Oxylo, Inc.
Publicly observedSan Diego, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Diego | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Oxylo, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | TZGHKYLCLET4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Oxygen reducing microcapsules for in vitro control of hypoxia
USD 603,604.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Oxygen reducing microcapsules for in vitro control of hypoxia
USD 229,072.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.